These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Serotonergic modulation of extrapyramidal motor disorders in mice and rats: role of striatal 5-HT3 and 5-HT6 receptors. Ohno Y; Imaki J; Mae Y; Takahashi T; Tatara A Neuropharmacology; 2011; 60(2-3):201-8. PubMed ID: 20813116 [TBL] [Abstract][Full Text] [Related]
29. Somatostatin antagonist potentiates haloperidol-induced catalepsy in the aged rat. Ionov ID; Severtsev NN Pharmacol Biochem Behav; 2012 Dec; 103(2):295-8. PubMed ID: 23036801 [TBL] [Abstract][Full Text] [Related]
30. Therapeutic potential of alpha2 adrenoceptor antagonism for antipsychotic-induced extrapyramidal motor disorders. Imaki J; Mae Y; Shimizu S; Ohno Y Neurosci Lett; 2009 Apr; 454(2):143-7. PubMed ID: 19429072 [TBL] [Abstract][Full Text] [Related]
31. Reversal of haloperidol-induced extrapyramidal side effects in cebus monkeys by 8-hydroxy-2-(di-n-propylamino)tetralin and its enantiomers. Christoffersen CL; Meltzer LT Neuropsychopharmacology; 1998 May; 18(5):399-402. PubMed ID: 9536454 [TBL] [Abstract][Full Text] [Related]
32. [Afobazole decreases motor side effects induced by haloperidol]. Seredenin SB; Garibova TA; Kuznetsova AL; Voronin MV; Iarkova MA; Voronina TA Eksp Klin Farmakol; 2009; 72(1):15-8. PubMed ID: 19334504 [TBL] [Abstract][Full Text] [Related]
34. Caffeine and muscarinic antagonists act in synergy to inhibit haloperidol-induced catalepsy. Moo-Puc RE; Góngora-Alfaro JL; Alvarez-Cervera FJ; Pineda JC; Arankowsky-Sandoval G; Heredia-López F Neuropharmacology; 2003 Sep; 45(4):493-503. PubMed ID: 12907310 [TBL] [Abstract][Full Text] [Related]
35. Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice. Akhtar M; Uma Devi P; Ali A; Pillai KK; Vohora D Fundam Clin Pharmacol; 2006 Aug; 20(4):373-8. PubMed ID: 16867021 [TBL] [Abstract][Full Text] [Related]
36. Nigella sativa Oil Reduces Extrapyramidal Symptoms (EPS)-Like Behavior in Haloperidol-Treated Rats. Malik T; Hasan S; Pervez S; Fatima T; Haleem DJ Neurochem Res; 2016 Dec; 41(12):3386-3398. PubMed ID: 27752803 [TBL] [Abstract][Full Text] [Related]
37. Biperiden and haloperidol plasma levels and extrapyramidal side effects in schizophrenic patients. Meszaros K; Lenzinger E; Hornik K; Schönbeck G; Hatzinger R; Langer G; Sieghart W; Aschauer HN Neuropsychobiology; 1997; 36(2):69-72. PubMed ID: 9267855 [TBL] [Abstract][Full Text] [Related]
38. Role of NMDA receptor subtypes in the induction of catalepsy and increase in Fos protein expression after administration of haloperidol. Yanahashi S; Hashimoto K; Hattori K; Yuasa S; Iyo M Brain Res; 2004 Jun; 1011(1):84-93. PubMed ID: 15140647 [TBL] [Abstract][Full Text] [Related]
39. The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine. Allan ER; Sison CE; Alpert M; Connolly B; Crichton J Psychopharmacol Bull; 1998; 34(1):71-4. PubMed ID: 9564201 [TBL] [Abstract][Full Text] [Related]
40. [Pharmacological characteristics of perospirone hydrochloride, a novel antipsychotic agent]. Ohno Y Nihon Yakurigaku Zasshi; 2000 Oct; 116(4):225-31. PubMed ID: 11084919 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]